drugset
Drugs / recombinant human annexin A5
last change Jan 2024 re-read 3 minutes ago

recombinant human annexin A5

Protein / enzyme biologic

Developed for
COVID-19 · infectious disease with sepsis
Investigated by
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London Health Sciences Foundation · Ontario Ministry of Colleges and Universities

Trials 1

today NCT04748757 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04748757 Apr 2021 → Apr 2022 COVID-19, infectious disease with sepsis London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as recombinant human annexin A5 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04748757 ↗
Modality Protein / enzyme biologic “Annexin A5 is a phosphatidylserine binding protein with anti-inflammatory, anticoagulant and anti-apoptotic properties.” PMID 38269269 ↗ Jan 2024